A ComboMatch Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations
Protocol: ECOG – EAY191-A6 SCHEMA EAY191-A6 Please Note: Below is a brief description of eligibility, please contact Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079, or (810)762-8038 to discuss the full eligibility requirements. Eligibility: Participants must have histologically confirmed BTC (IHC, EHC or GBC) that is unresectable or recurrent with a confirmed RAS/RAF/MEK/ERK pathway […]
A ComboMATCH Treatment Trial: Nilotinib and Paclitaxel in Patients with Prior Taxane Treated Solid Tumors
Protocol: ECOG – EAY191 -E4 SCHEMA EAY191-E4 Please Note: Below is a partial list of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 or (810)762-8038 to discuss the complete list of eligibility. Eligibility: Patient must be enrolled on the ComboMATCH Registration Protocol (EAY191) at the time of registration to the […]
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Protocol: ECOG – EAY191 SCHEMA EAY191 Please Note: Below is only a partial list of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810) 762-8181, (810) 762-8079 or (810) 762-8038 to discuss full eligibility requirements. Thank you! Eligibility: Patient must have measurable disease Patient must have an ECOG performance status between 0-2. […]
Phase II Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors
Protocol: ECOG – EAY191-S3 SCHEMA EAY191-S3 Please Note: Below is only brief eligibility, please contact the Genesys Hurley Cancer Institute Research Department at (810) 762-8181, (810) 762-8079, (810) 762-8038 to discuss full eligibility requirements. Eligibility: Participants must be enrolled on the ComboMATCH Master Registration Trial EAY191. Participants must have an activating AKT mutation (a known […]
Targeted Agent and Profiling Utilization Registry Study
PROTOCOL: TAPUR SCHEMA TAPUR Please Note: Below is partial eligibility, for full eligibility requirements, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! ELIGIBILITY: Patient (age ≥ 12 years*) with a histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer […]